Loading stock data…
ALKS
$35.47+0.48 (+1.37%)
Market ClosedLast close May 11
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alkermes plc in the Healthcare sector is trading at $35.47. The stock is currently near its 52-week high of $36.60, remaining 16.6% above its 200-day moving average. Technical signals show neutral RSI of 63 and bullish MACD crossover, explaining why ALKS maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 63) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$35.47
Potential Downside
7.5%
Whystock Fair Value$32.82
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus17 analysts
Mean target$45.71+28.9%
Range$34.00 – $58.00
Fundamentals
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.62B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
23.59
Beta
Defensive asset. Lower volatility than the S&P 500.
0.39
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
19.15%
Volume
Today's trading volume
1.57M
Recent News
Alkermes' Q1 Revenue Beat Highlights 'Underappreciated' Core Business, RBC Says
Alkermes' (ALKS) better-than-expected Q1 revenue highlights the "underappreciated nature" of the com
Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises
ALKS beats Q1 estimates as strong proprietary drug sales lift revenues by 28%, sending shares higher, while Lumryz adds a fresh growth driver.
Alkermes plc Q1 2026 Earnings Call Summary
Moby summary of Alkermes plc's Q1 2026 earnings call
Alkermes (ALKS) Q1 2026 Earnings Transcript
During the quarter, we closed the acquisition of Avadel Pharmaceuticals plc. The financial results announced today reflect the mid-February closing of the transaction and the integration of Avadel into our business, including 6 weeks of contribution from LUMRYZ, Avadel's once-at-bedtime sodium oxybate for the treatment of narcolepsy. Actual results could differ materially from these forward-looking statements. Please see Slide 2 of the accompanying presentation, our press release issued this morning and our most recent annual report filed with the SEC for important risk factors that could cause our actual results to differ materially from those expressed or implied in the forward-looking statements.
Alkermes Q1 Earnings Call Highlights
Alkermes (NASDAQ:ALKS) executives highlighted a strong start to 2026 and the completion of the Avadel Pharmaceuticals acquisition during the company’s first-quarter earnings call, pointing to accelerating scale across addiction and psychiatry brands and a new foothold in sleep medicine through LUMRY